Publications

BibTex format

@article{Khan:2018:10.1186/s13063-018-2487-9,
author = {Khan, HR and Kralj-Hans, I and Haldar, S and Bahrami, T and Clague, J and De, Souza A and Francis, D and Hussain, W and Jarman, J and Jones, DG and Mediratta, N and Mohiaddin, R and Salukhe, T and Jones, S and Lord, J and Murphy, C and Kelly, J and Markides, V and Gupta, D and Wong, T},
doi = {10.1186/s13063-018-2487-9},
journal = {Trials},
title = {Catheter ablation versus thoracoscopic surgical ablation in long standing persistent atrial fibrillation (CASA-AF): study protocol for a randomised controlled trial},
url = {http://dx.doi.org/10.1186/s13063-018-2487-9},
volume = {19},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Atrial fibrillation is the commonest arrhythmia which raises the risk of heart failure, thromboembolic stroke, morbidity and death. Pharmacological treatments of this condition are focused on heart rate control, rhythm control and reduction in risk of stroke. Selective ablation of cardiac tissues resulting in isolation of areas causing atrial fibrillation is another treatment strategy which can be delivered by two minimally invasive interventions: percutaneous catheter ablation and thoracoscopic surgical ablation. The main purpose of this trial is to compare the effectiveness and safety of these two interventions. METHODS/DESIGN: Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF) is a prospective, multi-centre, randomised controlled trial within three NHS tertiary cardiovascular centres specialising in treatment of atrial fibrillation. Eligible adults (n = 120) with symptomatic, long-standing, persistent atrial fibrillation will be randomly allocated to either catheter ablation or thoracoscopic ablation in a 1:1 ratio. Pre-determined lesion sets will be delivered in each treatment arm with confirmation of appropriate conduction block. All patients will have an implantable loop recorder (ILR) inserted subcutaneously immediately following ablation to enable continuous heart rhythm monitoring for at least 12 months. The devices will be programmed to detect episodes of atrial fibrillation and atrial tachycardia ≥ 30 s in duration. The patients will be followed for 12 months, completing appropriate clinical assessments and questionnaires every 3 months. The ILR data will be wirelessly transmitted daily and evaluated every month for the duration of the follow-up. The primary endpoint in the study is freedom from atrial fibrillation and atrial tachycardia at the end of the follow-up period. DISCUSSION: The CASA-AF Trial is a National Institute for Health
AU  - Khan,HR
AU  - Kralj-Hans,I
AU  - Haldar,S
AU  - Bahrami,T
AU  - Clague,J
AU  - De,Souza A
AU  - Francis,D
AU  - Hussain,W
AU  - Jarman,J
AU  - Jones,DG
AU  - Mediratta,N
AU  - Mohiaddin,R
AU  - Salukhe,T
AU  - Jones,S
AU  - Lord,J
AU  - Murphy,C
AU  - Kelly,J
AU  - Markides,V
AU  - Gupta,D
AU  - Wong,T
DO  - 10.1186/s13063-018-2487-9
PY  - 2018///
SN  - 1745-6215
TI  - Catheter ablation versus thoracoscopic surgical ablation in long standing persistent atrial fibrillation (CASA-AF): study protocol for a randomised controlled trial
T2  - Trials
UR  - http://dx.doi.org/10.1186/s13063-018-2487-9
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29458408
UR  - http://hdl.handle.net/10044/1/57327
VL  - 19
ER  -

Download

DrViasMarkides

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)